BioNTech (NASDAQ:BNTX) Now Covered by Berenberg Bank

Berenberg Bank started coverage on shares of BioNTech (NASDAQ:BNTX) in a research report report published on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $130.00 price objective on the stock.

A number of other equities analysts also recently commented on BNTX. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $110.00 to $125.00 in a research report on Tuesday. JPMorgan Chase & Co. lowered their price objective on BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a report on Monday, November 4th. HSBC boosted their target price on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 price target on shares of BioNTech in a research note on Thursday, November 14th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus target price of $138.79.

BioNTech Trading Up 4.4 %

Shares of BioNTech stock opened at $106.40 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $25.51 billion, a P/E ratio of -50.67 and a beta of 0.26. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company’s fifty day moving average is $113.68 and its two-hundred day moving average is $97.45.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the firm earned $0.73 EPS. Analysts forecast that BioNTech will post -3.68 earnings per share for the current year.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC grew its position in BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares during the last quarter. Covestor Ltd boosted its stake in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the last quarter. Capital International Sarl increased its stake in shares of BioNTech by 1.3% in the first quarter. Capital International Sarl now owns 24,058 shares of the company’s stock valued at $2,219,000 after buying an additional 310 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.